Prostate cancer is the frequently presented malignancy in men, and it is expected that nearly 300,000 people will be diagnosed with it in the United States in 2024. Generally, the five-year survival rate is quite positive at 97.5%, but this rate drops to around 30% in cases with advenced disease. Tumors arise from changes in the genetic material of the epithelial cells in the prostate gland and typically appear as adenocarcinomas. Adenocarcinoma of the prostate is found within the gland in a multifocal and heterogeneous manner. Metastases of prostate cancer are hormonally sensitive, the primary therapy became aimed at lowering testosterone levels to castration levels through surgical procedures or androgen deprivation therapy (ADT) via gonadotropin-releasing hormone.However, it is rarely used nowadays following the development of more potent and selective androgen synthesis inhibitors. Abiraterone acetate (AA) is a potent and selective inhibitor of cytochrome P17 (CYP17), a key enzyme in androgen synthesis, unlike ketoconazole, which inhibits various cytochrome P pathways. In this section, the effectiveness of Abiraterone Acetate treatment in metastatic prostate cancer aims to be explained, relying on the literature for support.